News

Under an exclusive worldwide research collaboration and licence agreement, the companies will be engaged in the development of small molecule inhibitors against several drug targets, which include the

As per the deal announced in December 2019, Charles River Laboratories offered to buy HemaCare for $25.40 per share. The California-based company, which will now operate under Charles

Leap will retain exclusive rights for the development, manufacturing, and commercialization of DKN-01 for the rest of the world. In addition, Leap announced entering into an agreement for

Dysport, an injectable form of a botulinum neurotoxin type A product, is a substance derived from Clostridium bacteria producing botulinum toxin type A (BoNT-A), which blocks the effective

BeiGene is a commercial-stage oncology firm focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Former Amgen global commercial operations executive vice president

Under the terms of the transaction agreement, GSK has received an upfront payment of €308m ($345m) and Bavarian Nordic is expected to pay a total of up to

As part of the collaboration and licence agreement, the companies will work together to detect small molecules designed to modulate specific pathways linked with a targeted indication within

The US regulator has approved Lynparza as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease

The clinical program, which will be co-funded by the companies, is expected to include three phase 3 pivotal trials in advanced non-small cell lung cancer (NSCLC), castration-resistant prostate